图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
真核基因表达评论综述™
影响因子: 1.841 5年影响因子: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN 打印: 1045-4403
ISSN 在线: 2162-6502

真核基因表达评论综述™

DOI: 10.1615/CritRevEukaryotGeneExpr.2019025430
pages 141-150

Prognostic Value of Ki-67/MIB-1 Expression in Meningioma Patients: A Meta-Analysis

Junhong Li
Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, P.R. China
Ruofei Liang
Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, P.R. China
Chen Song
Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, P.R. China
Yufan Xiang
Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, P.R. China
Yanhui Liu
Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, P.R. China

ABSTRACT

Ki-67/MIB-1 is the most widely used immumohistochemical marker to measure cell proliferation in recent years, and its high expression is significantly related to high malignancy and short survival cycle. This meta-analysis was conducted to confirm the prognostic value of Ki-67/MIB-1 in meningioma patients. A comprehensive search was carried out of mainstream electronic databases including Pubmed, EMBASE, Google Scholar, Web of Science, and Cochrane Library, and finally 10 studies containing 1,414 meningioma patients were included in the meta-analysis. The combined hazard ratio (HR) and its 95% confident intervals (CIs) were used to evaluate the association between Ki-67/MIB-1 expression and survival. High expression of Ki-67/MIB-1 was found to be significantly associated with low RFS (HR 3.31, 95% CI 1.62–6.78, P = 0.001, random effect) and PFS(HR 3.14, 95% CI 1.64–6.00, P = 0.001, fixed effect). Subgroup analysis was conducted to explore the potential heterogeneity. Results of the meta-analysis indicated that high expression of Ki-67/MIB-1 may serve as a useful biomarker for poor prognosis in meningioma patients.

REFERENCES

  1. Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamarides M, Menei P, Deruty R, Moreau JJ, Fevre-Montange M, Guyotat J, WHO grade II and III meningiomas: a study of prognostic factors. J Neuro-Oncol. 2009;95(3):367–75.

  2. Lamszus K. , Meningioma pathology, genetics, and biology. J Neuropathol Exper Neurol. 2004;63(4):275–86.

  3. Pecina-Slaus N, Kafka A, Vladusic T, Tomas D, Logara M, Skoko J, Hrascan R, Loss of p53 expression is accompanied by upregulation of beta-catenin in meningiomas: a concomitant reciprocal expression. Int J Exper Pathol. 2016;97(2):159–69.

  4. Pavelin S, Becic K, Forempoher G, Mrklic I, Pogorelic Z, Titlic M, Andelinovic S. , Expression of Ki-67 and p53 in meningiomas. Neoplasma. 2013;60(5):480–5.

  5. Babu S, Uppin SG, Uppin MS, Panigrahi MK, Saradhi V, Bhattacharjee S, Sahu BP, Purohit AK, Challa S. , Meningiomas: correlation of Ki67 with histological grade. Neurol India. 2011;59(2):204–7.

  6. Lanzafame S, Torrisi A, Barbagallo G, Emmanuele C, Alberio N, Albanese V, Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up. Pathol Res Practice. 2000;196(7):483–8.

  7. Pfisterer WK, Coons SW, Aboul-Enein F, Hendricks WP, Scheck AC, Preul MC., Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue. J Neuro-Oncol. 2008;87(1):43–50.

  8. Ohta M, Iwaki T, Kitamoto T, Takeshita I, Tateishi J, Fukui M., MIB1 staining index and scoring of histologic features in meningioma. Indicators for the prediction of biologic potential and postoperative management. Cancer. 1994;74(12):3176–89.

  9. Abry E, Thomassen IO, Salvesen OO, Torp SH. , The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study. Pathol Res Practice. 2010;206(12):810–5.

  10. Parmar MK, Torri V, Stewart L. , Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.

  11. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. , Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.

  12. Lau J, Ioannidis JP, Schmid CH. , Quantitative synthesis in systematic reviews. Annals Internal Med. 1997;127(9):820–26.

  13. Begg CB, Mazumdar M. , Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.

  14. Egger M, Davey Smith G, Schneider M, Minder C. , Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

  15. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A. , Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology. 2007;27(2):114–20.

  16. Champeaux C, Dunn L. , World Health Organization Grade II Meningioma: A 10-year retrospective study for recurrence and prognostic factor assessment. World Neurosurg. 2016;89:180–86.

  17. Hsu DW, Efird JT, Hedley-Whyte ET. , MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol Appl Neurobiol. 1998;24(6):441–52.

  18. Kim YJ, Ketter R, Steudel WI, Feiden W. , Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol. 2007;128(1):118–25.

  19. Kim MS, Kim KH, Lee EH, Lee YM, Lee SH, Kim HD, Kim YZ. , Results of immunohistochemical staining for cell cycle regulators predict the recurrence of atypical meningiomas. J Neurosurg. 2014;121(5):1189–200.

  20. Ohba S, Kobayashi M, Horiguchi T, Onozuka S, Yoshida K, Ohira T, Kawase T. , Long-term surgical outcome and biological prognostic factors in patients with skull base meningiomas. J Neurosurg. May 2011;114(5):1278–87.

  21. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. , The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer. 1998;82(11):2262–9.

  22. Vranic A, Popovic M, Cor A, Prestor B, Pizem J. , Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients. Neurosurgery. 2010;67(4):1124–32.

  23. Winther TL, Arnli MB, Salvesen O, Torp SH. , Phosphohistone-H3 proliferation index is superior to mitotic index and MIB-1 expression as a predictor of recurrence in human meningiomas. Am J Clin Pathol. 2016;146(4):510–20.

  24. Yamaguchi S, Terasaka S, Kobayashi H, Asaoka K, Motegi H, Nishihara H, Kanno H, Onimaru R, Ito YM, Shirato H, Houkin K. , Prognostic factors for survival in patients with high-grade meningioma and recurrence-risk stratification for application of radiotherapy. PLoS One. 2014;9(5): e97108.

  25. Yew A, Trang A, Nagasawa DT, Spasic M, Choy W, Garcia HM, Yang I. , Chromosomal alterations, prognostic factors, and targeted molecular therapies for malignant meningiomas. J Clin Neurosci. 2013;20(1):17–22.

  26. Bahnassy AA, Zekri AR, Alam El-Din HM, Aboubakr AA, Kamel K, El-Sabah MT, Mokhtar NM, The role of cyclins and cyclins inhibitors in the multistep process of HPV-associated cervical carcinoma. J Egyptian Natl Cancer Inst. 2006;18(4):292–302.

  27. Virman JP, Bono P, Luukkaala TH, Sunela KL, Kujala PM, Kellokumpu-Lehtinen PL., Combined angiogenesis and proliferation markers’ expressions as long-term prognostic factors in renal cell cancer. Clin Genitourinary Cancer. 2016;14(4):e283–289.

  28. Aleskandarany MA, Green AR, Benhasouna AA, Barros FF, Neal K, Reis-Filho JS, Ellis IO, Rakha EA, Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res. 2012;14(1):R3.

  29. Bertz S, Otto W, Denzinger S, Wieland WF, Burger M, Stohr R, Link S, Hofstadter F, Hartmann A, Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Eur Urol. 2014;65(1):218–26.

  30. Richterova R, Jurecekova J, Evinova A, Kolarovszki B, Benco M, De Riggo J, Sutovsky J, Mahmood S, Racay P, Dobrota D., Most frequent molecular and immunohistochemical markers present in selected types of brain tumors. Gen Physiol Biophys. 2014;33(3):259–79.

  31. Csonka T, Murnyak B, Szepesi R, Bencze J, Bognar L, Klekner A, Hortobagyi T. , Assessment of candidate immunohistochemical prognostic markers of meningioma recurrence. Folia Neuropathologica. 2016;54(2):114–26.

  32. Sandberg DI, Edgar MA, Resch L, Rutka JT, Becker LE, Souweidane MM. , MIB-1 staining index of pediatric meningiomas. Neurosurgery. 2001;48(3):590–5; discussion 595–7.

  33. Telugu RB, Chowhan AK, Rukmangadha N, Patnayak R, Phaneendra BV, Prasad BC, Reddy MK, Histopathological and immunohistochemical evaluation of meningiomas with reference to proliferative markers p53 and Ki-67. J Clin Diag Res. 2016;10(1):Ec15–19.

  34. Lefkowitz MA, Hinton DR, Weiss MH, Giannotta SL, Couldwell WT. , Prognostic variables in surgery for skull base meningiomas. Neurosurg Focus. 1997;2(4):e2.